Biomarkers and Targeted Therapeutics in Colorectal Cancer

Surgical Oncology Clinics of North America

Volumn 22, Issue 4, 2013, Pages 841-855

  Meguerditchian, Ari N ^a   Bullard Dunn, Kelli ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

APC; Colorectal cancer; CPG island methylation; Loss of heterozygosity; Microsatellite instability; Molecular biology; P53

Indexed keywords

APC PROTEIN; BEVACIZUMAB; MICRORNA; TUMOR MARKER;

APC GENE; CANCER PROGNOSIS; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; CPG ISLAND; DELETED IN COLON CANCER GENE; DNA METHYLATION; DRUG EFFICACY; DRUG RESPONSE; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MUTATOR GENE; ONCOGENE RAS; PERSONALIZED MEDICINE; REVIEW; RISK ASSESSMENT; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

APC; COLORECTAL CANCER; CPG-ISLAND METHYLATION; LOSS OF HETEROZYGOSITY; MICROSATELLITE INSTABILITY; MOLECULAR BIOLOGY; P53;

ANIMALS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883524972     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2013.07.002     Document Type: Review

References (108)

1. Verma M., Dunn B.K., Ross S., et al. Early detection and risk assessment: proceedings and recommendations from the Workshop on Epigenetics in Cancer Prevention. Ann N Y Acad Sci 2003, 983:298-319.
2. Verma M., Srivastava S. New cancer biomarkers deriving from NCI early detection research. Recent Results Cancer Res 2003, 163:72-84. [discussion: 264-66].
3. Zauber A.G., Winawer S.J., O'Brien M.J., et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. NEngl J Med 2012, 366:687-696.
4. Vogelstein B., Fearon E.R., Hamilton S.R., et al. Genetic alterations during colorectal-tumor development. NEngl J Med 1988, 319:525-532.
5. Fearon E.R., Cho K.R., Nigro J.M., et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990, 247:49-56.
6. Leslie A., Carey F.A., Pratt N.R., et al. The colorectal adenoma-carcinoma sequence. Br J Surg 2002, 89:845-860.
7. Sherr C.J. Cancer cell cycles. Science 1996, 274:1672-1677.
8. Irby R.B., Mao W., Coppola D., et al. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 1999, 21:187-190.
9. Kapitanovic S., Radosevic S., Kapitanovic M., et al. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 1997, 112:1103-1113.
10. Cartwright C. Intestinal cell growth control: role of Src tyrosine kinases. Gastroenterology 1998, 114:1335-1338.
11. Forgacs I. Oncogenes and gastrointestinal cancer. Gut 1988, 29:417-421.
12. Hamilton S.R. The molecular genetics of colorectal neoplasia. Gastroenterology 1993, 105:3-7.
13. Sikora K. Cancer genes in gastrointestinal malignancy. Baillieres Clin Gastroenterol 1990, 4:135-150.
14. Tahara E. Genetic alterations in human gastrointestinal cancers. The application to molecular diagnosis. Cancer 1995, 75:1410-1417.
15. Tsuboi K., Hirayoshi K., Takeuchi K., et al. Expression of the c-myc gene in human gastrointestinal malignancies. Biochem Biophys Res Commun 1987, 146:699-704.
16. Takayama T., Ohi M., Hayashi T., et al. Analysis of K-ras, APC, and beta-catenin inaberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. Gastroenterology 2001, 121:599-611.
17. Bourne H.R., Sanders D.A., McCormick F. The GTPase superfamily: conserved structure and molecular mechanism. Nature 1991, 349:117-127.
18. Spirio L.N., Samowitz W., Robertson J., et al. Alleles of APC modulate the frequency and classes of mutations that lead to colon polyps. Nat Genet 1998, 20:385-388.
19. Lamlum H., Ilyas M., Rowan A., et al. The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's 'two-hit' hypothesis. Nat Med 1999, 5:1071-1075.
20. Korinek V., Barker N., Morin P.J., et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997, 275:1784-1787.
21. Morin P.J., Sparks A.B., Korinek V., et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275:1787-1790.
22. Goss K.H., Groden J. Biology of the adenomatous polyposis coli tumor suppressor. JClin Oncol 2000, 18:1967-1979.
23. van de Wetering M., Sancho E., Verweij C., et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002, 111:241-250.
24. Peifer M., Polakis P. Wnt signaling in oncogenesis and embryogenesis-a look outside the nucleus. Science 2000, 287:1606-1609.
25. Mann B., Gelos M., Siedow A., et al. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA 1999, 96:1603-1608.
26. Kastan M.B., Onyekwere O., Sidransky D., et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991, 51:6304-6311.
27. Kuerbitz S.J., Plunkett B.S., Walsh W.V., et al. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992, 89:7491-7495.
28. Woods D.B., Vousden K.H. Regulation of p53 function. Exp Cell Res 2001, 264:56-66.
29. Lane D.P. Cancer. p53, guardian of the genome. Nature 1992, 358:15-16.
30. Rosty C., Young J.P., Walsh M.D., et al. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Mod Pathol 2013, 26(6):825-834.
31. Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann N Y Acad Sci 2000, 910:121-137. [discussion: 37-9].
32. Baker S.J., Preisinger A.C., Jessup J.M., et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990, 50:7717-7722.
33. Kikuchi-Yanoshita R., Konishi M., Ito S., et al. Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma infamilial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res 1992, 52:3965-3971.
34. Kirsch D.G., Kastan M.B. Tumor-suppressor p53: implications for tumor development and prognosis. JClin Oncol 1998, 16:3158-3168.
35. Russo A., Bazan V., Iacopetta B., et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. JClin Oncol 2005, 23:7518-7528.
36. Hedrick L., Cho K.R., Fearon E.R., et al. The DCC gene product in cellular differentiation and colorectal tumorigenesis. Genes Dev 1994, 8:1174-1183.
37. Thiagalingam S., Lengauer C., Leach F.S., et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996, 13:343-346.
38. Cho K.R., Oliner J.D., Simons J.W., et al. The DCC gene: structural analysis and mutations in colorectal carcinomas. Genomics 1994, 19:525-531.
39. Popat S., Houlston R.S. Asystematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 2005, 41:2060-2070.
40. Sun X.F., Rutten S., Zhang H., et al. Expression of the deleted in colorectal cancer gene is related to prognosis in DNA diploid and low proliferative colorectal adenocarcinoma. JClin Oncol 1999, 17:1745-1750.
41. Keino-Masu K., Masu M., Hinck L., et al. Deleted in Colorectal Cancer (DCC) encodes a netrin receptor. Cell 1996, 87:175-185.
42. Eppert K., Scherer S.W., Ozcelik H., et al. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996, 86:543-552.
43. Miyaki M., Iijima T., Konishi M., et al. Higher frequency of Smad4 gene mutationinhuman colorectal cancer with distant metastasis. Oncogene 1999, 18:3098-3103.
44. Abdel-Rahman W.M., Mecklin J.P., Peltomaki P. The genetics of HNPCC: application to diagnosis and screening. Crit Rev Oncol Hematol 2006, 58:208-220.
45. Peltomaki P. Deficient DNA mismatch repair: a common etiologic factor for colon cancer. Hum Mol Genet 2001, 10:735-740.
46. Schwitalle Y., Kloor M., Eiermann S., et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 2008, 134:988-997.
47. Weisenberger D.J., Siegmund K.D., Campan M., et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006, 38:787-793.
48. Shen L., Kondo Y., Rosner G.L., et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. JNatl Cancer Inst 2005, 97:1330-1338.
49. Das P.M., Singal R. DNA methylation and cancer. JClin Oncol 2004, 22:4632-4642.
50. van Engeland M., Derks S., Smits K.M., et al. Colorectal cancer epigenetics: complex simplicity. JClin Oncol 2011, 29:1382-1391.
51. Lao V.V., Grady W.M. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 2011, 8:686-700.
52. Rosty C., Walsh M.D., Walters R.J., et al. Multiplicity and molecular heterogeneity of colorectal carcinomas in individuals with serrated polyposis. Am J Surg Pathol 2013, 37:434-442.
53. Laiho P., Kokko A., Vanharanta S., et al. Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis. Oncogene 2007, 26:312-320.
54. Makinen M.J. Colorectal serrated adenocarcinoma. Histopathology 2007, 50:131-150.
55. O'Brien M.J., Yang S., Mack C., et al. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol 2006, 30:1491-1501.
56. Jass J.R., Do K.A., Simms L.A., et al. Morphology of sporadic colorectal cancer with DNA replication errors. Gut 1998, 42:673-679.
57. Buecher B., Cacheux W., Rouleau E., et al. Role of microsatellite instability in the management of colorectal cancers. Dig Liver Dis 2013, 45(6):441-449.
58. Thibodeau S.N., Bren G., Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993, 260:816-819.
59. Lothe R.A., Peltomaki P., Meling G.I., et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 1993, 53:5849-5852.
60. Gryfe R., Kim H., Hsieh E.T., et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. NEngl J Med 2000, 342:69-77.
61. Sargent D.J., Marsoni S., Monges G., et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. JClin Oncol 2010, 28:3219-3226.
62. Zaanan A., Flejou J.F., Emile J.F., et al. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. Clin Cancer Res 2011, 17:7470-7478.
63. Sinicrope F.A., Foster N.R., Thibodeau S.N., et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. JNatl Cancer Inst 2011, 103:863-875.
64. Popat S., Hubner R., Houlston R.S. Systematic review of microsatellite instability and colorectal cancer prognosis. JClin Oncol 2005, 23:609-618.
65. Ogino S., Meyerhardt J.A., Irahara N., et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 2009, 15:7322-7329.
66. Kim G.P., Colangelo L.H., Wieand H.S., et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. JClin Oncol 2007, 25:767-772.
67. Ribic C.M., Sargent D.J., Moore M.J., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. NEngl J Med 2003, 349:247-257.
68. Kelley R.K., Venook A.P. Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?. Clin Colorectal Cancer 2011, 10:73-80.
69. Lievre A., Bachet J.B., Boige V., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. JClin Oncol 2008, 26:374-379.
70. Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F., et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007, 67:2643-2648.
71. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. JClin Oncol 2007, 25:1658-1664.
72. Jimeno A., Messersmith W.A., Hirsch F.R., et al. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. JClin Oncol 2009, 27:1130-1136.
73. Di Nicolantonio F., Martini M., Molinari F., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. JClin Oncol 2008, 26:5705-5712.
74. Siena S., Sartore-Bianchi A., Di Nicolantonio F., et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. JNatl Cancer Inst 2009, 101:1308-1324.
75. Bokemeyer C., Van Cutsem E., Rougier P., et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur JCancer 2012, 48:1466-1475.
76. Bokemeyer C., Bondarenko I., Hartmann J.T., et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011, 22:1535-1546.
77. Vale C.L., Tierney J.F., Fisher D., et al. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer Treat Rev 2012, 38:618-625.
78. De Roock W., Claes B., Bernasconi D., et al. Effects of KRAS, BRAF, NRAS, andPIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11:753-762.
79. Soeda H., Shimodaira H., Watanabe M., et al. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. Int J Clin Oncol 2012, [Epub ahead of print].
80. Mao C., Yang Z.Y., Hu X.F., et al. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol 2012, 23:1518-1525.
81. Barratt P.L., Seymour M.T., Stenning S.P., et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 2002, 360:1381-1391.
82. Bertagnolli M.M., Niedzwiecki D., Compton C.C., et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. JClin Oncol 2009, 27:1814-1821.
83. Kim S.T., Lee J., Park S.H., et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol 2010, 66:659-667.
84. O'Connell M.J., Lavery I., Yothers G., et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. JClin Oncol 2010, 28:3937-3944.
85. Clark-Langone K.M., Wu J.Y., Sangli C., et al. Biomarker discovery for colon cancer using a 761 gene RT-PCR assay. BMC Genomics 2007, 8:279.
86. Gray R.G., Quirke P., Handley K., et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. JClin Oncol 2011, 29:4611-4619.
87. Webber E.M., Lin J.S., Evelyn P.W. Oncotype DX tumor gene expression profiling instage II colon cancer. Application: prognostic, risk prediction. PLoS Curr 2010, 2.
88. Maak M., Simon I., Nitsche U., et al. Independent validation of a prognostic genomic signature (coloprint) for patients with stage ii colon cancer. Ann Surg 2013, 257:1053-1058.
89. Tan I.B., Tan P. Genetics: an 18-gene signature (ColoPrint(R)) for colon cancer prognosis. Nat Rev Clin Oncol 2011, 8:131-133.
90. Salazar R., Roepman P., Capella G., et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. JClin Oncol 2011, 29:17-24.
91. Hyslop T., Waldman S.A. Molecular staging of node negative patients with colorectal cancer. JCancer 2013, 4:193-199.
92. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. NEngl J Med 2004, 350:2335-2342.
93. Cohen M.H., Gootenberg J., Keegan P., et al. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 2007, 12:356-361.
94. Kozloff M., Yood M.U., Berlin J., et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009, 14:862-870.
95. Golubovskaya V.M., Kweh F.A., Cance W.G. Focal adhesion kinase and cancer. Histol Histopathol 2009, 24:503-510.
96. Dunn K.B., Heffler M., Golubovskaya V.M. Evolving therapies and FAK inhibitors for the treatment of cancer. Anticancer Agents Med Chem 2010, 10:722-734.
97. Heffler M., Golubovskaya V., Conroy J., et al. Fak and has inhibition synergistically decrease colon cancer cell viability and affect expression of critical genes. Anticancer Agents Med Chem 2013, 13:584-594.
98. Rossi S., Di Narzo A.F., Mestdagh P., et al. MicroRNAs in colon cancer: a roadmap for discovery. FEBS Lett 2012, 586:3000-3007.
99. Tokarz P., Blasiak J. The role of microRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment. Acta Biochim Pol 2012, 59:467-474.
100. Schetter A.J., Okayama H., Harris C.C. The role of microRNAs in colorectal cancer. Cancer J 2012, 18:244-252.
101. Luo X., Burwinkel B., Tao S., et al. MicroRNA signatures: novel biomarker for colorectal cancer?. Cancer Epidemiol Biomarkers Prev 2011, 20:1272-1286.
102. Oberg A.L., French A.J., Sarver A.L., et al. miRNA expression in colon polyps provides evidence for a multihit model of colon cancer. PLoS One 2011, 6:e20465.
103. Ryan B.M., Robles A.I., Harris C.C. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010, 10:389-402.
104. Link A., Balaguer F., Shen Y., et al. Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev 2010, 19:1766-1774.
105. Shibuya H., Iinuma H., Shimada R., et al. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology 2010, 79:313-320.
106. Kulda V., Pesta M., Topolcan O., et al. Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases. Cancer Genet Cytogenet 2010, 200:154-160.
107. Nielsen B.S., Jorgensen S., Fog J.U., et al. High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis 2011, 28:27-38.
108. Schetter A.J., Leung S.Y., Sohn J.J., et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008, 299:425-436.